Literature DB >> 19898787

[Prevention of perioperative venous thromboembolism in children].

Werner Streif1.   

Abstract

Venous thromboembolic events (VTE) occur in children at the time of surgery. Few guidelines about how to assess the risk and provide prophylaxis have been developed and published so far. It is uncertain if any of these guidelines have been adopted into clinical practice. The article discusses the specific differences of the haemostatic system throughout childhood, risk assessment, choice and dosing of antithrombotic agents, difficulties in drug monitoring and side effects of treatment including HIT. Current available recommendations and guidelines are summarized. Current evidence on which to base risk stratification and prevention of VTE for children undergoing surgery consists mainly of cohort studies, case series, case reports and expert opinion. Many suggestions are merely extrapolated from results from clinical trials in adults. Primary healthy children who undergo minor surgery including circumcision, herniotomy and appendectomy do not need antithrombotic prophylaxis. Children with multiple risk factors for VTE including severe underlying conditions and long-term immobilization, children with central venous lines and children with a history of VTE should be considered to receive VTE prophylaxis. Older children (Tanner II+) should be treated following adult guidelines. Standard unfractionated heparin and low molecular heparin are the most frequently recommended antithrombotic drugs. Decision for VTE prophylaxis must widely be based on individual risk assessment by experienced physicians. Newly developed scores and guidelines may provide assistance. Well designed clinical studies in children that provide proper evidence on risk assessment for VTE at the time of surgery and investigate safety and efficacy of antithrombotic prophylaxis/treatment are urgently needed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19898787     DOI: 10.1007/s10354-009-0712-6

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  53 in total

1.  Influence of activated factor VII concentrates on thrombin generation in full-term and preterm neonates.

Authors:  W Streif; R Borum Andreasen; B Paes; L Berry; L Xu; M Andrew; A K Chan
Journal:  Blood Coagul Fibrinolysis       Date:  2000-04       Impact factor: 1.276

2.  Risk factors for venous thrombosis in Swedish children and adolescents.

Authors:  Olof Rask; Erik Berntorp; Rolf Ljung
Journal:  Acta Paediatr       Date:  2005-06       Impact factor: 2.299

3.  Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands.

Authors:  C H van Ommen; H Heijboer; H R Büller; R A Hirasing; H S Heijmans; M Peters
Journal:  J Pediatr       Date:  2001-11       Impact factor: 4.406

4.  Neonatal symptomatic thromboembolism in Germany: two year survey.

Authors:  U Nowak-Göttl; R von Kries; U Göbel
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1997-05       Impact factor: 5.747

5.  An open-label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial.

Authors:  Patricia Massicotte; Jim A Julian; Michael Gent; Karen Shields; Velma Marzinotto; Barbara Szechtman; Maureen Andrew
Journal:  Thromb Res       Date:  2003-01-25       Impact factor: 3.944

6.  Development of the human coagulation system in the full-term infant.

Authors:  M Andrew; B Paes; R Milner; M Johnston; L Mitchell; D M Tollefsen; P Powers
Journal:  Blood       Date:  1987-07       Impact factor: 22.113

Review 7.  Heparin-induced thrombocytopenia.

Authors:  A Greinacher
Journal:  J Thromb Haemost       Date:  2009-07       Impact factor: 5.824

8.  Maturation of the hemostatic system during childhood.

Authors:  M Andrew; P Vegh; M Johnston; J Bowker; F Ofosu; L Mitchell
Journal:  Blood       Date:  1992-10-15       Impact factor: 22.113

Review 9.  Unfractionated heparin therapy in infants and children.

Authors:  Fiona Newall; Linda Johnston; Vera Ignjatovic; Paul Monagle
Journal:  Pediatrics       Date:  2009-02-16       Impact factor: 7.124

10.  Nadroparin therapy in pediatric patients with venous thromboembolic disease.

Authors:  C Heleen van Ommen; Erik-Jan van den Dool; Marjolein Peters
Journal:  J Pediatr Hematol Oncol       Date:  2008-03       Impact factor: 1.289

View more
  1 in total

Review 1.  Direct thrombin and factor Xa inhibitors in children: a quest for new anticoagulants for children.

Authors:  Werner Streif; Walter Ageno
Journal:  Wien Med Wochenschr       Date:  2011-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.